ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Responses To Control Grants Guidelines Pour Into NCI, Some From Grantsmen “Old Pros”

November 23, 1974

“Roller-Coaster Budget” For NIH Criticized On Capitol Hill; $1 Billion Cut By FY 2000?

March 17, 1995

Compliance Grants Awarded, Contract Pending On Differences In Black/White Survival

November 19, 1982

Gleevec Improves Survival Of CML In Accelerated Phase

December 27, 2002

Cancer Pain Treatment Guide Published By NCCN, ACS

April 27, 2001

Bisphosphonates May Reduce Recurrent Breast Cancer

December 25, 2009